A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP.
Phase of Trial: Phase I/II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Cenegermin (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions
- Acronyms Lumos
- Sponsors Dompe Spa
- 24 Jul 2018 Status changed from active, no longer recruiting to completed.
- 16 Mar 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 16 Mar 2015 Planned End Date changed from 1 Apr 2015 to 1 Nov 2015 as per ClinicalTriasl.gov record.